Immix Biopharma (NASDAQ:IMMX) Earns “Market Outperform” Rating from Citizens Jmp

Immix Biopharma (NASDAQ:IMMX)‘s stock had its “market outperform” rating reaffirmed by analysts at Citizens Jmp in a research report issued on Friday,Benzinga reports. They currently have a $23.00 target price on the stock. Citizens Jmp’s price target points to a potential upside of 182.21% from the company’s current price.

IMMX has been the subject of several other research reports. Morgan Stanley started coverage on shares of Immix Biopharma in a research note on Wednesday. They issued an “overweight” rating and a $20.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Mizuho initiated coverage on Immix Biopharma in a research note on Monday, February 9th. They set an “outperform” rating and a $14.00 price target on the stock. Finally, HC Wainwright upped their price target on Immix Biopharma from $12.00 to $15.00 and gave the stock a “buy” rating in a report on Friday. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Immix Biopharma presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Immix Biopharma Stock Performance

NASDAQ:IMMX opened at $8.15 on Friday. Immix Biopharma has a 1 year low of $1.34 and a 1 year high of $11.61. The stock has a fifty day moving average price of $7.77 and a two-hundred day moving average price of $5.26. The stock has a market capitalization of $431.71 million, a price-to-earnings ratio of -9.16 and a beta of 0.25.

Immix Biopharma (NASDAQ:IMMX) last issued its earnings results on Wednesday, March 25th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.12). On average, analysts predict that Immix Biopharma will post -0.87 EPS for the current year.

Institutional Investors Weigh In On Immix Biopharma

A number of large investors have recently added to or reduced their stakes in IMMX. Janus Henderson Group PLC purchased a new position in Immix Biopharma during the 4th quarter valued at about $20,471,000. Eventide Asset Management LLC purchased a new stake in shares of Immix Biopharma in the fourth quarter valued at about $13,331,000. Marshall Wace LLP grew its position in shares of Immix Biopharma by 3,495.4% in the fourth quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock valued at $10,349,000 after purchasing an additional 1,923,708 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Immix Biopharma during the 4th quarter worth approximately $8,681,000. Finally, Adage Capital Partners GP L.L.C. purchased a new position in shares of Immix Biopharma during the 4th quarter worth approximately $7,845,000. 11.26% of the stock is owned by institutional investors and hedge funds.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.